What are Lipid-Based Drug Delivery Systems (LBDDS)?
Lipid-based drug delivery systems are a focal point in pharmaceutical science due to their ability to enhance the solubility, stability, and bioavailability of poorly soluble drugs. These systems offer a promising approach to amplify the therapeutic impact of drugs while minimizing their adverse effects. Lipid-based drug delivery systems encompass a range of formulations utilizing lipids as carriers for drug molecules. These systems can be categorized based on their composition and structure, including liposomes, lipid nanoparticles, solid lipid nanoparticles, nanostructured lipid carriers, and lipid micelles. They offer distinct advantages in terms of drug loading capacity, stability, and release kinetics. Currently, lipid-based drug delivery systems are being extensively investigated for broad applications in drug delivery and therapy. These systems exhibit promising potential in delivering anticancer drugs, anti-inflammatory drugs, antibacterial drugs, and vaccines. Notably, the use of lipid nanoparticles for targeted drug delivery to specific tissues or cells, such as tumors, inflammatory tissues, or infected cells, is an area of active research.
Lipid Formulation Development Services
BOC Sciences provides cutting-edge lipid formulation development services to meet the pharmaceutical industry's growing demand for innovative drug delivery solutions. With an experienced team of scientists and state-of-the-art facilities, we are at the forefront of lipid formulation research and development. Service capabilities cover formulation design, optimization, scale-up and manufacturing. Whether developing nanoemulsions, liposomes or solid lipid nanoparticles, BOC Sciences works closely with customers to customize lipid formulations to address specific drug delivery challenges. In addition, we offer a comprehensive range of lipid products for quick access to our customers.
Catalog | Name | CAS | Molecular Weight | Category |
---|---|---|---|---|
BPG-3287 | 25-Hydroxy-Cholesterol | 2140-46-7 | 402.65 | Sterols |
BPG-3312 | 7Keto-25-hydroxy cholesterol | 64907-23-9 | 416.64 | Sterols |
BPG-3294 | 20(S)-Hydroxycholesterol | 516-72-3 | 402.65 | Sterols |
BPG-3299 | 7β,27-dihydroxy Cholesterol | 240129-43-5 | 418.65 | Sterols |
BPG-3153 | C15 Ceramide (d18:1/15:0) | 67492-15-3 | 523.87 | Bile Acid Standards |
BPG-3125 | 7-Keto Cholesterol-[d7] | 127684-08-6 | 407.68 | Bile Acid Standards |
What is Lipid Based Formulation Classification?
The routes available for administering lipid-based drug delivery systems (LBDDS) include oral, gastrointestinal, ocular, nasal, skin/transdermal, and vaginal routes. Among these, the oral route is the most favored due to its non-invasiveness, cost-effectiveness, and lower likelihood of side effects compared to routes like injections. It is also considered the simplest and most convenient method for chronic treatment. However, during the initial stages of development, formulation strategies based on rational and systematic approaches are crucial to prevent instability and poor correlation between in vitro and in vivo results, thereby enhancing the success rate of formulation development.
Formulation type | Material | Characteristics | Advantages | Disadvantages |
---|---|---|---|---|
Type I | Oils without surfactants (e.g., tri-, di-, and monoglycerides) | Nondispersing requires digestion | Generally recognized as safe (GRAS) status; simple; and excellent capsule compatibility | Formulation has poor solvent capacity unless drug is highly lipophilic |
Type II | Oils and water insoluble surfactants | SEDDS formed without water-soluble components | Unlikely to lose solvent capacity on dispersion | Turbid o/w dispersion (particle size 0.25-2 μm) |
Type III | Oils, surfactants, and cosolvents (both water-insoluble and water-soluble excipients) | SEDDS/SMEDDS formed with water-soluble components | Clear or almost clear dispersion, drug absorption without digestion | Possible loss of solvent capacity on dispersion, less easily digested |
Type IV | Water-soluble surfactants and cosolvents | Formulation disperses typically to form a micellar solution | Formulation has good solvent capacity for many drugs | Likely loss of solvent capacity on dispersion may not be digestible |
Factors Affecting Lipid-based Delivery System
Solubility
Although lipids (fatty acid derivatives) are the primary components of the formulation, one or more surfactants and potentially hydrophilic co-solvents may be necessary to aid in dissolution and enhance dispersion properties. Surfactants are categorized based on their hydrophilic-lipophilic balance (HLB) values. Lower values (≤10) indicate higher lipophilicity, while higher values (≥10) indicate higher hydrophilicity. To guide the formulation design process, most lipids used in these oral formulations have a specified 'required HLB' value, which corresponds to the optimal HLB of the surfactant blend needed to emulsify the oil in water. Various emulsifiers can be employed for different formulations, depending on their HLB values, as outlined in Table 2.
Common name/type | Examples |
Low HLB (<10) emulsifier | |
Phosphatidylcholine and phosphatidylcholine/solvent mixtures | Phosphatidylcholine, phosphatidylcholine in propylene glycol, phosphatidylcholine in medium chain triglycerides, and phosphatidylcholine in safflower oil/ethanol |
Unsaturated polyglycolized glycerides | Oleoyl macrogolglycerides, linoleoyl macrogolglycerides |
Sorbitan esters | Sorbitan monooleate, sorbitan monostearate, sorbitan monolaurate, and sorbitan monopalmitate |
High HLB (>10) emulsifier | |
Polyoxyethylene sorbitan esters | Polysorbate 20, polysorbate 40, polysorbate 60, and polysorbate 80 |
Polyoxyl castor oil derivatives | Polyoxyl 35 castor oil, polyoxyl 40 hydrogenated castor oil |
Polyoxyethylene polyoxypropylene block copolymer | Poloxamer 188, poloxamer 407 |
Saturated polyglycolized glycerides | Lauroyl macrogolglycerides, stearoyl macrogolglycerides |
PEG-8 caprylic/capric glycerides | Caprylocaproyl macrogolglycerides |
Vitamin E derivative | Tocopherol PEG succinate |
Table 2. Emulsifiers used in lipid-based formulations.
Dispersion
The examination of emulsification and dispersion properties of formulations containing candidate drugs with adequate solubility in aqueous carriers is essential. An initial assessment can be conducted by observing preparations mixed with water under a microscope. Effective emulsification is indicated by vigorous mixing at the water/formulation interface, involving diffusion and stranding mechanisms. Additionally, it is crucial that no drug precipitation occurs once the preparation is fully mixed with the aqueous medium. Utilizing techniques such as laser scattering to measure the particle size of emulsion droplets can be highly beneficial in identifying promising formulations.
Fig. 1. Ternary phase diagram for lipid formulations (J Pharm (Cairo). 2014, 2014: 801820).
The ternary phase diagram is commonly used to identify the emulsification structural type and study the behavior of the preparation during dilution (see Fig. 1). The line connecting points A and B illustrates the dilution process of a mixture initially containing 35% surfactant and 65% oil. This path traverses through the water-in-oil microemulsion and lamellar liquid crystal phases before reaching a stable bicontinuous oil-in-water microemulsion upon further dilution. While constructing the entire phase diagram may not always be necessary, understanding the structural evolution along the dilution path is crucial for ensuring the formation of a stable dispersed structure post-dilution. Combining low and high HLB surfactants typically leads to smaller emulsion droplet sizes compared to using a single surfactant.
Digestion
The impact of intestinal lipases on the behavior of lipid preparations in the gastrointestinal tract is significant and must be considered in the design process. It has been well established that lipids that are non-dispersible but digestible, such as triglycerides, can undergo metabolism by lipases to form mono/diglycerides and fatty acids, which helps emulsify any remaining oil. Therefore, to ensure the necessary small particle size and large surface area for effective drug release, a high quantity of surfactants may not be necessary. In 2000, Pouton introduced a classification system for lipid formulations based on the formulation's composition and the role of digestion in promoting dispersion, as outlined in Table 3.
Type I | Type II | Type IIIA | Type IIIB | |
% triglycerides or mixed glycerides | 100 | 40-80 | 40-80 | <20 |
% surfactants | - | 20-60 (HLB < 12) | 20-40 (HLB > 11) | 20-50 (HLB > 11) |
% hydrophilic cosolvents | - | - | 0-40 | 20-50 |
Particle size of dispersion (nm) | Coarse | 100-250 | 100-250 | 50-100 |
Significance of aqueous dilution | Limited importance | Solvent capacity unaffected | Some loss of solvent capacity | Significant phase changes and potential loss of solvent capacity |
Significance of digestibility | Crucial requirement | Not crucial, but likely to occur | Not crucial, but may be inhibited | Not required and not likely to occur |
Table 3. Pouton's classification of lipid-based delivery systems.
Absorption
The ultimate objective of any oral lipid preparation is to ensure the effective absorption of drugs by intestinal mucosal cells. In Fig. 2, the process of lipid-based pharmaceutical preparations in the intestinal environment is illustrated. Initially, the components are dispersed to create lipid droplets (for type I preparations) or emulsion droplets (for type II-III). Subsequently, the digestion products undergo lipolysis and are dissolved by bile acids to form colloidal mixed micelles. It is hypothesized that the drug is then extracted from the mixed micelles of emulsion oil droplets and bile salts and taken up by the mucosal cells of the intestinal wall.
Fig. 2. Intestinal absorption of lipid-based pharmaceutical formulations (J Pharm (Cairo). 2014, 2014: 801820).
Benefits of Lipid-based Delivery Systems
- Drugs are released in a controlled and targeted manner.
- Pharmaceutical stability.
- High and enhanced drug content (compared to other carriers).
- Feasibility of carrying lipophilic and hydrophilic drugs.
- It is biodegradable and biocompatible.
- Auxiliary materials are widely used.
- The versatility of the recipe.
- Low risk status.
- The passive, non-invasive vesicle formation system can be immediately commercialized.
Design Guidelines of Lipid-based Delivery System
Lipid-based formulations will remain crucial for preparing poorly soluble drugs, although designing these formulations can pose challenges. Currently, the seven guidelines for lipid preparation design can be summarized as follows:
- Maintain drug solubility in the formulation, post-dispersion, and post-digestion.
- Characteristics of colloidal substances post-processing in the gastrointestinal environment may enhance absorption more than the preparation's characteristics.
- Higher lipid (> 60%) and lower surfactant (< 30%) and cosolvent (< 10%) proportions generally improve drug dissolution after dilution.
- Medium-chain triglycerides enhance drug solubility and stability, while long-chain triglycerides are better at forming bile salt lipid colloids, leading to increased bioavailability.
- IIIB SMEDDS formulation yields smaller droplet sizes post-dispersion, but efficacy is more reliant on surfactant characteristics, with indigestible surfactants often offering higher bioavailability.
- Type IV formulations (surfactants/co-solvents) may benefit from using two surfactants instead of one for more effective dispersion.
- Type IV preparations can increase drug solubility but require careful design to prevent drug precipitation post-dispersion.
Featured Lipid Products from BOC Sciences
Catalog | Name | CAS | Molecular Weight | Category |
---|---|---|---|---|
BPG-3113 | 25-Hydroxy Cholesterol-[d6] | 88247-69-2 | 408.69 | Bile Acid Standards |
BPG-3614 | C13-112-tri-tail | 1381861-96-6 | 743.3 | Branched Lipid |
BPG-3617 | C13-113-tetra-tail | 1381861-97-7 | 910.6 | Branched Lipid |
BPG-3884 | DSPE-NHS | 1383932-86-2 | 945.2 | Phospholipid |
BPG-3890 | DLPC | 6542-05-8 | 782.1 | Phospholipid |
BPG-3891 | DOPE-Mal | 2295813-15-7 | 895.2 | Phospholipid |
Reference
- Shrestha, H. et al. Lipid-Based Drug Delivery Systems. J Pharm (Cairo). 2014, 2014: 801820.
Why BOC Sciences?
-
Large Stock
More than 2000+ products in inventory
-
Global Delivery
Warehouses in multiple cities to ensure fast delivery
-
mg to kg
Multi specification for academic research and industrial production
-
24/7 Technical Support
Strict process parameter control to ensure product quality
Technical Support
- Aqueous Two-Phase System (ATPS) Technique
- Capillary Electrophoresis (CE) Technique
- Enzyme-linked immunosorbent assay (ELISA) Technique
- High performance liquid chromatography (HPLC) Technique
- Hydrophobic Interaction Chromatography (HIC) Technique
- PEGylated Protein Purification Techniques
- Radiolabeling Technique
- SDS-PAGE Technique
- Ultrafiltration Technique
Products
- Lipids
- PEG Derivatives by Structure
-
PEG Derivatives by Functional Group
- Acrylate/Acrylamide/Methacrylate PEG
- Aldehyde (Ald/CHO)PEG
- Alkyne PEG
- Amino PEG, PEG amine(-NH2)
- Azide PEG, Azido PEG(-N3)
- Biotin PEG
- Boc/Fmoc protected amine PEG
- Carboxylic Acid(-COOH) PEG
- Cholesterol PEG
- DBCO PEG
- DNP PEG
- DSPE PEG
- Epoxide glycidyl ether PEG
- FITC PEG
- Folate PEG
- Halide (chloride, bromide) PEG
- Hydrazide PEG
- Hydroxyl(-OH) PEG
- Maleimide(-MAL) PEG
- NHS ester PEG
- Nitrophenyl carbonate (NPC) PEG
- Norbornene PEG
- Olefin/Alkene/Vinyl PEG
- Orthopyridyl disulfide (OPSS) PEG
- Phosphate PEG
- Rhodamine PEG
- SCM PEG
- Silane PEG
- SPDP PEG
- Sulfonate (tosyl, mesyl, tresyl) PEG
- tert-Butyl protected carboxylate PEG
- Thiol(-SH) PEG
- Vinylsulfone PEG
- PEG Copolymers
-
PEG Raw Materials
- Small-molecule Polyethylene Glycol
- Polyethylene Glycol 1000
- Polyethylene Glycol 10000
- Polyethylene Glycol 1500
- Polyethylene Glycol 200
- Polyethylene Glycol 2000
- Polyethylene Glycol 20000
- Polyethylene Glycol 400
- Polyethylene Glycol 4000
- Polyethylene Glycol 600
- Polyethylene Glycol 6000
- Polyethylene Glycol 800
- Polyethylene Glycol 8000
Resources
-
Technical Information
- Aqueous Two-Phase System (ATPS) Technique
- Capillary Electrophoresis (CE) Technique
- Enzyme-linked immunosorbent assay (ELISA) Technique
- High performance liquid chromatography (HPLC) Technique
- How to Perform Polyethylene Glycol (PEG) Modification?
- Hydrophobic Interaction Chromatography (HIC) Technique
- Introduction of Polyethylene Glycol (PEG)
- Ion Exchange Chromatography (IEX) Technique
- PEG for Chemical Synthesis
- PEG for Cosmetic Application
- PEG for Drug Delivery
- PEG for Imaging Diagnosis
- PEG for Pharmaceutical Preparation
- PEG for Tissue Engineering
- PEG Purification Techniques of Plasmid DNA
- PEGylated Protein Purification Techniques
- Polyethylene Glycol (PEG) Modifier Selection Guide
- Radiolabeling Technique
- SDS-PAGE Technique
- Size Exclusion Chromatography (SEC) Technique
- Ultrafiltration Technique
-
Industry News
- Applications of PEG-DSPE: Drug Carriers and Drug Delivery
- Applications of Polyethylene Glycol (PEG) as Medical Devices
- Cholesterol: Definition, Structure, Synthesis, Types and Functions
- Classification of Lipid-Based Vaccine Adjuvants
- FDA approved PEGylated Products
- FDA-Approved Antibody-Drug Conjugates up to 2024
- How are Liposomes Different from Micelles?
- How Lipid Nanoparticles (LNPs) Deliver RNA Drugs?
- Hyaluronic Acid & PEGylated Hyaluronic Acid
- Ionizable Lipids for RNA Delivery
- Lipid Classification and Drug Delivery Systems
- Lipid Formulations: Key Absorption-Enhancing Technologies in New Drug Development
- Lipid-Drug Conjugates (LDCs) for Nanoparticle Drug Delivery
- Liposome in Drug Delivery
- Overview of Liposome Preparation Process
- PEG in Pharmaceutical Preparations (I): Solvents, Lubricants, Adhesives and More
- PEG in Pharmaceutical Preparations (II): Stabilizers, Plasticizers and Modification Materials
- PEG Linkers in Antibody Drug Conjugates and PROTACs
- PEG-DSPE Block Copolymers and Their Derivatives
- PEGylated Drugs: Definition, Structure, Classification and Benefits
- PEGylated RGD Peptides: A Promising Tool for Targeted Drug Delivery
- Pharmacokinetics and Bioanalysis of PEGylated Drugs
- Polyethylene Glycol (PEG) Modified Targeting Nanomaterials
- Preparation Method of PEG Hydrogel
- The PROTAC Technology in Drug Development
- Vaccines: Definition, History, Ingredients, Types and Mechanism of Action
- What are Lipid Excipients and Their Applications?
- What are Lipid Nanoparticles and Their Applications?
- What are Lipid-Drug Conjugates (LDCs)?
- What are Lipids?
- What are Monodispersed and Polydispersed PEGs?
- What are PEG Lipids?
- What are Phospholipids?
- What are Sterols? - Definition, Structure, Function, Examples and Uses
- What is Biotinylation and Biotinylated PEG?
- What is Click Chemistry?
- What is Hydrogel?
- What is Methoxy Polyethylene Glycol (mPEG)?
- What is Nanogels and Its Applications?
- What is the Formulation of Lipid Nanoparticles (LNPs)?
Our Feature
BOC Sciences supplies a unique variety of PEG derivatives and functional PEG polymers. Our products offer the most diverse collection of reactivity, ready-to-use functionality, and molecular weight options that you will not find anywhere else.
![PEGylation of Peptides and Proteins](/peg/images/pcSide-pic2.png)
PEGylation of Peptides
and Proteins
Reduce the Immunogenicity of Peptide/Protein Drugs
Learn More
APPLICATIONS
![APPLICATIONS](/peg/images/pcSide-pic3.png)
PEG linkers For Drug
Improved Circulation Half-Life
Learn More
Have Customer Reviewed On Us?
Chat With Us